Skip to content

Study of UK Adults With Congenital Adrenal Hyperplasia.

Cross-Sectional Multi-Centre Study of UK Adults With Congenital Adrenal Hyperplasia.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00749593
Acronym
CaHASE
Enrollment
25
Registered
2008-09-09
Start date
2004-08-31
Completion date
2011-12-31
Last updated
2024-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Adrenal Hyperplasia

Keywords

Congenital Adrenal Hyperplasia, Quality of Life, Genotype, Metabolic outcomes

Brief summary

Congenital Adrenal Hyperplasia (CAH) is one of the commonest inherited diseases, affecting 1:14,200 live births. It is the result of a genetic defect in one of the enzymes (in most cases 21-hydroxylase) required for cortisol biosynthesis, leading to reduced levels of cortisol and aldosterone, increased ACTH concentrations and consequently increased adrenal androgen production. Patients suffer from problems with growth and development and as adults patients may have problems with fertility, virilisation in women, testicular masses in men and both men and women have an impaired quality of life. Patients have to take life-long therapy. Despite its frequency knowledge surrounding the management of adults with CAH remains fairly limited. There has been a lot of work describing the management of children with CAH but to date there is no consensus on how to manage adults. To address this issue a number of adult endocrinologists in the UK under the auspices of the Society for Endocrinology have established a country wide study (CaHASE) to undertake research in order to set standards of care for adult patients with CAH. In CAH the severity of the symptoms experienced by affected individuals varies depending on the mutation and the genetic background of the individual. The ability to tailor CAH therapy on an individual basis, as determined by the severity of the underlying defect and an understanding of the likely natural history of the disease, is a key goal in clinical management. Correlation of phenotype (clinical status) and genotype (the underlying 21 hydroxylase gene mutation) will facilitate stratification of severity and provide an important contribution to the debate on potential mechanisms of individualised therapy. For instance it may become clear that certain CAH genotypes are associated with specific long term outcomes. In time, this could lead to suggesting different treatment strategies in certain groups. Moreover, genotype data are important if we are to address the relative contribution of environment (e.g. treatment) vs. genetics on long term outcomes. This multi-centre study aims to: 1. \- Investigate the medical health of adults with congenital adrenal hyperplasia. 2. \- Investigate the relationship between the genotype of the patient and the phenotype. 3. \- Investigate the quality of life of adults with congenital adrenal hyperplasia.

Interventions

None listed

Sponsors

Society for Endocrinology
CollaboratorOTHER
The Clinical Endocrinology Trust
CollaboratorUNKNOWN
Sheffield Teaching Hospitals NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age over 18 * Clinical and genetic diagnosis of congenital adrenal hyperplasia

Exclusion criteria

* Pregnant females * Under 18

Design outcomes

Primary

MeasureTime frame
The anthropometric, metabolic, endocrine and quality of life variables of adults with congenital adrenal Hyperplasia will be compared to reference ranges for the normal population.End of Study

Secondary

MeasureTime frame
To identify areas where further research is required and to inform on the day to day management of adults with CAHEnd of study

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026